| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| HLA-E*0103 & B2M & CMV UL40 (VMPPRTVIL) | Biotinylated Human HLA-E*01:03&B2M&CMV UL40 (VMPPRTVIL) Complex Protein (Monomer, MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug |   | |||
| HLA-E*0103 & B2M & CMV UL40 (VMPPRTVIL) | PE-Labeled Human HLA-E*01:03&B2M&CMV UL40 (VMPPRTVIL) Tetramer Protein | Human | HEK293 | $410.00 25ug | |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Xaluritamig | AMG-509 | Phase 3 Clinical | Xencor Inc, Amgen Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| 89Zr-DFO-MSTP2109A | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center, Genentech Inc | Prostatic Neoplasms | Details | |
| STEAP1 CART Cell Therapy(PromiCell) | Phase 2 Clinical | PromiCell Therapeutics Inc, Fred Hutchinson Cancer Research Center | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details | |
| ABBV-969 | ABBV-969; ABBV969 | Phase 1 Clinical | Abbvie Inc, Immunogen Inc | Prostatic Neoplasms, Castration-Resistant | Details |
